Trump Executive Order Tracker | Akin Public Policy and Lobbying

Regulatory Relief to Promote Domestic Production of Critical Medicines (Trump EO Tracker)

May 5, 2025

Reading Time : 1 min
Trump Executive Order Tracker | Akin Public Policy and Lobbying

This order streamlines the regulation of manufacturing pharmaceutical products and inputs to facilitate the restoration of a robust domestic pharmaceutical manufacturing base.

Within 180 days, the order directs the Secretary of Health and Human Services, through the FDA Commissioner, to review existing regulations and guidance that pertain to the development of domestic pharmaceutical manufacturing and take steps to eliminate any duplicative or unnecessary requirements in such regulations and guidance; maximize the timeliness and predictability of agency review; and streamline and accelerate the development of domestic pharmaceutical manufacturing.

Within 90 days of the order, the FDA Commissioner is directed to develop and advance improvements to the risk-based inspection regime that ensures routine reviews of overseas manufacturing facilities involved in the supply of United States medicines, funded by increased fees on foreign manufacturing facilities and the FDA Commissioner must publicly disclose the annual number of inspections that the FDA conducts on such foreign facilities.

Within 180 days, the order instructs the Administrator of the Environmental Protection Agency (EPA) to take action to update regulations and guidance that apply to the inspection and approval of new and expanded manufacturing capacity of pharmaceutical products, active pharmaceutical ingredients, key starting materials, and associated raw materials in the United States to eliminate any duplicative or unnecessary requirements and maximize the timeliness and predictability of agency review.

Within 180 days of the order, the Secretary of the Army, acting through the Assistant Secretary of the Army for Civil Works, shall review the nationwide permits issued under section 404 of the Clean Water Act of 1972 (33 U.S.C. 1344) and section 10 of the Rivers and Harbors Appropriation Act of 1899 (33 U.S.C. 403) to determine whether an activity-specific nationwide permit is needed to facilitate the efficient permitting of pharmaceutical manufacturing facilities.

Additional Documentation

Share This Insight

Related Content

Trump Executive Order Tracker

The significant number of executive orders published by the Trump Administration cut across dozens of industries and areas of law. This searchable tool breaks down the orders and their impacts on specific industries and with in-depth analysis of specific orders.

Previous Entries

Trump Executive Order Tracker

August 28, 2025

Expands national security exclusions from federal labor-management relations by adding specific units in the Bureau of Reclamation, Department of Commerce, NASA, and the U.S. Agency for Global Media to the list of agencies performing intelligence or national security functions. It also extends the deadline for related exclusions issued by the Secretaries of Defense and Veterans Affairs. 

...

Read More

Trump Executive Order Tracker

August 28, 2025

Directs the Attorney General to investigate whether federal grant funds are being illegally used for lobbying or partisan political activities, citing concerns over misuse and potential violations of federal law. 

...

Read More

Trump Executive Order Tracker

August 28, 2025

Directs the General Services Administration to prioritize classical and traditional architecture as the preferred style for major federal public buildings, update its policies accordingly, and require architects and design reviewers to have expertise in these styles. Establishes stricter review and presidential notification requirements for approving designs that deviate from this preference. 

...

Read More

Trump Executive Order Tracker

August 25, 2025

Directs federal agencies to immediately deploy additional personnel, investigate safety violations, and establish specialized units to restore public safety in Washington, DC, with provisions for rapid nationwide deployment if needed. 

...

Read More

Trump Executive Order Tracker

August 25, 2025

Directs federal agencies to detain dangerous arrestees in Washington, DC, pursue federal charges where possible, and apply pressure on the District to end its cashless bail policies. 

...

Read More

Trump Executive Order Tracker

August 25, 2025

Directs federal agencies to prioritize the prosecution of individuals who desecrate the American flag in ways that incite violence or violate existing laws and authorizes immigration consequences for foreign nationals involved in such acts.

...

Read More

Trump Executive Order Tracker

August 25, 2025

Directs federal agencies to identify and potentially suspend funding to jurisdictions that have substantially eliminated cash bail for crimes posing public safety risks, including offenses involving violent, sexual, or indecent acts, or burglary, looting, or vandalism. 

...

Read More

Trump Executive Order Tracker

August 21, 2025

Establishes the "America by Design" initiative to modernize and improve the usability and aesthetics of federal digital and physical services. Creates a National Design Studio and appoints a Chief Design Officer to lead efforts across agencies. 
 
Heads of agencies must consult with the Chief Design Officer and implement the "America by Design" initiative at their respective agencies and produce initial results by July 4, 2026. 

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.